Latest & greatest articles for propranolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on propranolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on propranolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for propranolol

41. Comparison of antihypertensive effects of captopril and propranolol in essential hypertension.

Comparison of antihypertensive effects of captopril and propranolol in essential hypertension. 7005474 1981 03 27 1981 03 27 2016 10 17 0098-7484 245 5 1981 Feb 06 JAMA JAMA Comparison of antihypertensive effects of captopril and propranolol in essential hypertension. 478-82 The antihypertensive effects of the oral converting enzyme inhibitor captopril and of propranolol were evaluated in a single-blind trial of 12 weeks in 19 ambulatory men with moderated essential hypertension (supine (...) diastolic blood pressure [DPB], 100 to 120 mm Hg after receiving placebo for two weeks) whose sodium intake was unrestricted. The captopril group included 12 patients and the propranolol group seven. After the initial dose-finding period of four weeks, supine DBP was significantly reduced in eight patients receiving captopril and in four of the patients receiving propranolol. In these patients DBP decreased throughout the following eight weeks. In the remaining patients from each group, DBP

JAMA1981

42. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension.

Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. 6115999 1981 11 22 1981 11 22 2015 06 16 0140-6736 2 8246 1981 Sep 12 Lancet (London, England) Lancet Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. 539-43 Participants in the Medical Research (...) Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs. The trial is single-blind. 23 582 patient-years of observation have been completed so far, 10 684 on active drugs and 12 898 on placebos. The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos. Other

Lancet1981

43. Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients.

Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. 6112329 1981 07 20 1981 07 20 2015 06 16 0140-6736 1 8226 1981 Apr 25 Lancet (London, England) Lancet Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. 920-1 Placebo or propranolol was given randomly of two groups of 12 adults with cirrhosis who had recently held from oesophageal or gastric varices or from acute gastric erosions. During three months' follow-up 5 patients (...) in the placebo and none in the propranolol group had recurrent gastrointestinal bleeding. Lebrec D D Nouel O O Bernuau J J Bouygues M M Rueff B B Benhamou J P JP eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Placebos 9Y8NXQ24VQ Propranolol AIM IM Clinical Trials as Topic Esophageal and Gastric Varices prevention & control Humans Liver Cirrhosis complications Peptic Ulcer Hemorrhage prevention & control Placebos Propranolol therapeutic use Random Allocation

Lancet1981

44. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study.

Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. 7029276 1982 01 09 1982 01 09 2013 11 21 0028-4793 305 23 1981 Dec 03 The New England journal of medicine N. Engl. J. Med. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. 1371-4 It has been suggested that because propranolol decreases portal venous pressure, it may prevent gastrointestinal bleeding associated (...) with portal hypertension. We randomly assigned 74 patients with cirrhosis, who were admitted because of gastrointestinal bleeding, to either oral propranolol given in doses that reduced the heart rate by 25 per cent (38 patients) or to a placebo (36 patients). The proportion of patients free of recurrent gastrointestinal bleeding one year after inclusion in this study was 96 per cent in the propranolol group and 50 per cent in the placebo group (P less than 0.0001). We conclude that continuous

NEJM1981

45. Benzodiazepine withdrawal symptoms and propranolol.

Benzodiazepine withdrawal symptoms and propranolol. 6111632 1981 06 13 1981 06 13 2015 06 16 0140-6736 1 8219 1981 Mar 07 Lancet (London, England) Lancet Benzodiazepine withdrawal symptoms and propranolol. 520-2 40 patients seen in general practice and psychiatric outpatient clinics who had taken lorazepam or diazepam alone in regular dosage for a mean period of 3.6 years had their benzodiazepine replaced by propranolol (60--120 mg/day) or placebo for two weeks under double-blind conditions (...) . Depending on the criteria for the definition of an abstinence syndrome, 27--45% of the patients had withdrawal symptoms during the study. Propranolol did not affect the drop-out rate or the incidence of withdrawal symptoms but significantly reduced their severity in patients completing the study. The percentage fall in serum levels of desmethyldiazepam in patients who experienced withdrawal symptoms after stopping diazepam was significantly greater in patients with no withdrawal symptoms. Tyrer P P

Lancet1981

46. Effect of propranolol and prazosin on blood lipids. The Oslo Study.

Effect of propranolol and prazosin on blood lipids. The Oslo Study. 6104255 1980 08 28 1980 08 28 2015 06 16 0140-6736 2 8184 1980 Jul 05 Lancet (London, England) Lancet Effect of propranolol and prazosin on blood lipids. The Oslo Study. 4-6 In 23 hypertensive men, aged 47-55, propranolol reduced serum high-density-lipoprotein (HDL) cholesterol by 13% reduced the ratio of HDL to low-density-lipoprotein (LDL)+very-low-density-lipoprotein (VLDL) cholesterol by 15%, increased total triglycerides (...) by 24%, and increased serum uric acid by 10%. Prazosin reduced total serum cholesterol by 9%, LDL+VLDL cholesterol by 10%, and total triglycerides by 16%. These changes are statistically highly significant. On combined treatment with propranolol and prazosin HDL cholesterol was still significantly reduced but changes in other blood lipids were small and insignificant. Uric acid remained elevated. When decisions about long-term therapy are made, such metabolic effects might be of special importance

Lancet1980

47. Propranolol--a medical treatment for portal hypertension?

Propranolol--a medical treatment for portal hypertension? 6105342 1980 10 27 1980 10 27 2015 06 16 0140-6736 2 8187 1980 Jul 26 Lancet (London, England) Lancet Propranolol--a medical treatment for portal hypertension? 180-2 Continuous, oral administration of propranolol at doses which reduced the heart-rate by 25% produced a sustained decrease in portal venous pressure in cirrhotic patients with portal hypertension. This effect of propranolol might be useful in preventing recurrent bleeding due (...) to ruptured oesophageal varices in patients with portal hypertension. Lebrec D D Nouel O O Corbic M M Benhamou J P JP eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 9Y8NXQ24VQ Propranolol AIM IM Administration, Oral Cardiac Output drug effects Clinical Trials as Topic Esophageal and Gastric Varices complications Gastrointestinal Hemorrhage prevention & control Heart Rate drug effects Humans Hypertension, Portal drug therapy Liver Circulation drug effects

Lancet1980

48. Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension.

Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. 85937 1979 06 29 1979 06 29 2015 06 16 0140-6736 1 8118 1979 Mar 31 Lancet (London, England) Lancet Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. 697-9 Sixteen patients with moderate essential hypertension completed a double-blind crossover trial with four treatment periods each of 6 weeks. They received (...) in random order: placebo; tienilic acid 250 mg/day; propranolol 80 mg twice daily; and tienilic acid 250 mg/day combined with propranolol 80 mg twice daily. Average blood-pressure in the lying position was 22.6/13.1 kPa (169/98 mm Hg) on placebo; 21.0/12.5 (157/94) on tienilic aicd; 21.2/12.0 (159/90) on propranolol, and 18.9/11.5 (142/86) on tienilic acid combined with propranolol. The effects of tienilic acid and propranolol on blood-pressure were additive and there were no statistically significant

Lancet1979

49. Protective effect of propranolol in threatened myocardial infarction.

Protective effect of propranolol in threatened myocardial infarction. 81925 1979 01 15 1979 01 15 2015 06 16 0140-6736 2 8096 1978 Oct 28 Lancet (London, England) Lancet Protective effect of propranolol in threatened myocardial infarction. 907-9 Propranolol 0.1 mg/kg intravenously followed by 320 mg orally over 27 h was given to 20 randomly selected patients within 4 h of the onset of suspected myocardial infarction unaccompanied by diagnostic electrocardiographic changes. Patients given (...) propranolol had fewer completed infarcts as assessed by serial electrocardiograms, a lower frequency of serum-creatine-kinase levels above the normal range, and lower peak serum-creatine-kinase levels than 23 control subjects. This evidence suggests that threatened myocardial infarction can in some cases be prevented by early beta-adrenoceptor blockade. Norris R M RM Clarke E D ED Sammel N L NL Smith W M WM Williams B B eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R

Lancet1978

50. Propranolol as an adjunct to the treatment of schizophrenia.

Propranolol as an adjunct to the treatment of schizophrenia. 71397 1977 11 30 1977 11 30 2015 06 16 0140-6736 2 8038 1977 Sep 17 Lancet (London, England) Lancet Propranolol as an adjunct to the treatment of schizophrenia. 575-8 Propranolol contributed usefully to the practical management of patients with chronic schizophrenia whose florid symptoms had not remitted with major tranquillisers. 14 patients who had received an average equivalent of 954 mg per day of chlorpromazine for 10 years were (...) given, in addition, either propranolol or a placebo for 12 weeks. Both groups had improved by the twelfth week, but the propranolol group had improved significantly more. Yorkston N J NJ Zaki S A SA Pitcher D R DR Gruzelier J H JH Hollander D D Sergeant H G HG eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Placebos 9Y8NXQ24VQ Propranolol U42B7VYA4P Chlorpromazine AIM IM Adult Blood Pressure drug effects Chlorpromazine administration & dosage

Lancet1977